Samstag, 31. Juli 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE
ZGynO_CINIII

Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma

Rekrutierend

NCT-Nummer:
NCT04753073

Studienbeginn:
Februar 2021

Letztes Update:
23.06.2021

Wirkstoff:
-

Indikation (Clinical Trials):
Neoplasms, Carcinoma in Situ, Cervical Intraepithelial Neoplasia

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University Hospital Tuebingen

Collaborator:
-

Studienleiter

Martin Weiss, Dr. med.q
Principal Investigator
Department of Women's Health, University Hospital Tuebingen

Kontakt

Studienlocations
(1 von 1)

University Hospital Tuebingen, Department of Women's Health
72076 Tuebingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Miriam Linneweh, Dr. rer. nat
Phone: +4970712982211
E-Mail: miriam.linneweh@med.uni-tuebingen.de
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

Cervical intraepithelial neoplasms (CIN), classified into severity levels CIN I to III, can

be precursors to cervical cancer (CC), the world's third most common cancer in women (270,000

deaths / year), which radical therapies are often associated with lifelong severe physical

and emotional stress. Cross-sectional studies found a prevalence for CIN of 62 per 1,000

women and incidences of 1.2 (CIN I), 0.8 (CIN II) and 0.7 (CIN III) per 1,000 women per year

(highest incidence of CIN between 20 and 24 years) age). The standard therapy for the

treatment of CIN III by LEEP excision is associated with an increase in mortality of 17%. CIN

III, in particular, is associated with a significant decline in quality of life,

psychological well-being and sexual health, although on average only about 12% of CIN III

lesions progress to invasive CC. The resulting over-treatment (in around 8-9 out of 10

patients) with invasive procedures is a serious problem for affected women, health care

providers and the health economy.

The NIPP treatment is a tissue-sparing, pain-free, easy to carry out and outpatient treatment

method without anesthesia and hospitalization. A non-randomized, one-arm feasibility study at

the Department of Women's Health (649 / 2017BO1) already showed the effectiveness of a NIPP

treatment.

Clinical implications for CIN III:

- A previous NIPP treatment should significantly reduce the invasiveness of the LEEP

excision.

- If the oncological safety of NIPP treatment is comparable (histological complete

remission of CIN III), NIPP is to be established as a safe alternative to LEEP excision

in the future.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Age ≥ 18 years

- Histologically confirmed CIN III

- Clearly visible transformation zone of the portio and margins of the lesions

according to T1 / T2

- signed written consent

Exclusion Criteria:

- Not fully visible transformation zone

- Indication of an invasive disease

- Serious cardiovascular diseases

- Patients who only want to undergo a LEEP excision

Studien-Rationale

Primary outcome:

1. Rate of histological complete remission (Time Frame - 8 Weeks):
Rate of histological complete remission of the CIN III at the time of the LEEP excision



Secondary outcome:

1. Rate of partial histological remission (Time Frame - 8 Weeks):
Rate of partial histological remission of the CIN I / II

2. Rate of decreased HPV viral load (Time Frame - 8 Weeks):
Rate of decreased HPV viral load in tissues

3. Pain and quality of life (Time Frame - 8 Weeks):
Pain and quality of life (Freiburg index for patient satisfaction) Pain assessment i) previous to, ii) during, iii) 4 h after, iv) 2 days after, v) 1 week after NIPP treatment, min/max values: 0 - 10, higher scores mean worse outcome Satisfaction assessment, min/max values: 1-6, higher scores mean worse outcome

Studien-Arme

  • Experimental: NIPP
    Treatment of the NIPP group with physical low-temperature plasma, subsequently within 8 weeks LEEP-Exzision
  • No Intervention: Controll
    LEEP-Exzision

Geprüfte Regime

  • Non-invasive physical plasma:
    Treatment with non invasive physical low-temperature plasma

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose